Home > Products > Novel inhibitors

Ilunocitinib

  Cat. No.:  DC47030   Featured
Chemical Structure
1187594-14-4
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86-021-58447131
Get Quotation Now
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
Ilunocitinib (compound 27) is a JAK inhibitor (extracted from patent WO2009114512A1).
Chemicals PropertiesBiological activity COA & MSDSRelated productsDatasheet
Cas No.: 1187594-14-4
Chemical Name: Ilunocitinib
Synonyms: Ilunocitinib;N3TB5AH8B9;LY3411067;2-[1-cyclopropylsulfonyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile;Ilunocitinib [USAN];GTPL11670;WHO 11894;(1-(Cyclopropanesulfonyl)-3-(4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-1H-pyrazol-1-yl)azetidin-3-yl)acetonitrile;2-(3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-1-(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile;3-Azetidineaceton;2-(1-cyclopropylsulfonyl-3-(4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)pyrazol-1-yl)azetidin-3-yl)acetonitrile;2-(1-cyclopropylsulfonyl-3-(4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)pyrazol-1-yl)azetidin-3-yl)acetonitrile;2-(1-cyclopropylsulfonyl-3-(4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)pyrazol-1-yl)azetidin-3-yl)acetonitrile;2-(1-cyclopropylsulfonyl-3-(4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)pyrazol-1-yl)azetidin-3-yl)acetonitrile;2-(1-cyclopropylsulfonyl-3-(4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)pyrazol-1-yl)azetidin-3-yl)acetonitrile;2-(1-cyclopropylsulfonyl-3-(4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)pyrazol-1-yl)azetidin-3-yl)acetonitrile;2-(1-cyclopropylsulfonyl-3-(4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)pyrazol-1-yl)azetidin-3-yl)acetonitrile;G18507;G18507;G18507;G18507;G18507;G18507;G18507;HY-132819;HY-132819;HY-132819;HY-132819;HY-132819;HY-132819;HY-132819;EX-A9647;EX-A9647;EX-A9647;EX-A9647;EX-A9647;EX-A9647;EX-A9647;ILUNOCITINIB [INN];ILUNOCITINIB [INN];ILUNOCITINIB [INN];ILUNOCITINIB [INN];ILUNOCITINIB [INN];ILUNOCITINIB [INN];ILUNOCITINIB [INN];1187594-14-4;1187594-14-4;1187594-14-4;1187594-14-4;1187594-14-4;1187594-14-4;1187594-14-4;RVOUEXFKIYNODQ-UHFFFAOYSA-N;RVOUEXFKIYNODQ-UHFFFAOYSA-N;RVOUEXFKIYNODQ-UHFFFAOYSA-N;RVOUEXFKIYNODQ-UHFFFAOYSA-N;RVOUEXFKIYNODQ-UHFFFAOYSA-N;RVOUEXFKIYNODQ-UHFFFAOYSA-N;3-Azetidineacetonitrile, 1-(cyclopropylsulfonyl)-3-(4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-1H-pyrazol-1-yl)-;3-Azetidineacetonitrile, 1-(cyclopropylsulfonyl)-3-(4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-1H-pyrazol-1-yl)-;3-Azetidineacetonitrile, 1-(cyclopropylsulfonyl)-3-(4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-1H-pyrazol-1-yl)-;RVOUEXFKIYNODQ-UHFFFAOYSA-N;3-Azetidineacetonitrile, 1-(cyclopropylsulfonyl)-3-(4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-1H-pyrazol-1-yl)-;3-Azetidineacetonitrile, 1-(cyclopropylsulfonyl)-3-(4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-1H-pyrazol-1-yl)-;3-Azetidineacetonitrile, 1-(cyclopropylsulfonyl)-3-(4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-1H-pyrazol-1-yl)-;CHEMBL4802241;CHEMBL4802241;3-Azetidineacetonitrile, 1-(cyclopropylsulfonyl)-3-(4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-1H-pyrazol-1-yl)-;CHEMBL4802241;CHEMBL4802241;CHEMBL4802241;CHEMBL4802241;DA-74442;DA-74442;DA-74442;DA-74442;CHEMBL4802241;DA-74442;DA-74442;UNII-N3TB5AH8B9;UNII-N3TB5AH8B9;UNII-N3TB5AH8B9;DA-74442;UNII-N3TB5AH8B9;UNII-N3TB5AH8B9;CS-0204093;UNII-N3TB5AH8B9;CS-0204093;CS-0204093;UNII-N3TB5AH8B9;CS-0204093;CS-0204093;SCHEMBL870650;SCHEMBL870650;CS-0204093;CS-0204093;SCHEMBL870650;SCHEMBL8706...
SMILES: S(C1([H])C([H])([H])C1([H])[H])(N1C([H])([H])C(C([H])([H])C#N)(C1([H])[H])N1C([H])=C(C2=C3C([H])=C([H])N([H])C3=NC([H])=N2)C([H])=N1)(=O)=O
Formula: C17H17N7O2S
M.Wt: 383.4276
Purity: 98%
Sotrage: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
MSDS
COA
LOT NO. DOWNLOAD
2018-0101
Cat. No. Product name Field of application
DC72210 NDI-034858(Zasocitinib) NDI034858 is a TYK2 inhibitor, target TYK2 JH2 domain with binding constant Kd of <200 pM.
DC72043 VVD-118313 VVD-118313 (compound 5a) is a potent, selective JAK1 inhibitor. VVD-118313 targets an isoform-restricted allosteric cysteine to block JAK1-dependent trans-phosphorylation and cytokine signaling. VVD-118313 can be used for research of cancer.
DC70831 TD-1473 TD-1473 (Izencitinib, TD1473, JNJ 8398) is a potent, selective, oral gut-selective pan-JAK inhibitor with pKi of 10.0/10.0/8.8/9.5 for human recombinant JAK1, JAK2, JAK3 and TYK2.TD-1473 inhibited cytokine-induced phosphorylation of STAT1 in mouse primary colonic epithelial cells with pIC50 values for inhibition against IL-6, IFNα and IFNγ were 7.3, 6.8 and 7.0.TD-1473 demonstrated JAK inhibitory activity in ex vivo mouse colon and human IBD patient colonic tissue. TD-1473 (Izencitinib) is under development for the treatment of ulcerative colitis.
DC70233 AZD4604 AZD4604 (AZD-4604) is a potent, selective Janus-associated kinase 1 (JAK1) inhibitor with anti-inflammatory effect.
DC47591 JAK-IN-14 JAK-IN-14 is a potent and selective JAK1 inhibitor, with an IC50 of <5 μM. JAK-IN-14 is >8-fold more selective for JAK1 than JAK2 and JAK3 (Patent WO2016119700A1, compound 16).
DC47132 JAK1-IN-8 JAK1-IN-8, a potent JAK1 inhibitor (IC50<500 nM), compound 28, extracted from patent WO2016119700A1.
DC47066 Ifidancitinib Ifidancitinib is a potent and selective inhibitor of JAK kinases 1/3. Ifidancitinib can be used in studies of allergies, asthma and autoimmune diseases.
DC47038 Fosifidancitinib Fosifidancitinib is a potent and selective inhibitor of JAK kinases 1/3. Fociatinib is used in studies of allergies, asthma and autoimmune diseases.
DC47030 Ilunocitinib Ilunocitinib (compound 27) is a JAK inhibitor (extracted from patent WO2009114512A1).
DC40513 BD750 BD750, an effective immunosuppressant and a JAK3/STAT5 inhibitor, inhibits IL-2-induced JAK3/STAT5-dependent T cell proliferation, with IC50 values of 1.5 μM and 1.1 μM in mouse and human T cells, respectively.
X
Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.
Site Map|Privacy PolicyCopyright © 2018-2020 All Rights Reserved. Technical Support:KuuJia